Phase 1/2 Study Of Pf-06463922 (an Alk/ros1 Tyrosine Kinase Inhibitor) In Patients With Advanced Non-small Cell Lung Cancer Harboring Specific Molecular Alterations
Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient
reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer
patients and ROS1+ advanced non small cell lung cancer patients .
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society